PHARMACEUTICALS

Addresses

National Health Care and Prescription Drug Policies: Robert Ingram, S11720-S11722 [20NO]

Amendments

Diseases: improve access to HIV/AIDS-related treatments and services in sub-Saharan Africa and other developing countries (H.R. 2069), S6700, S6716, S6727 [12JY]

Drugs: enhance competition for prescription drugs by increasing enforcement of existing antitrust laws relative to brand name and generic drugs (S. 754), S11316, S11339, S11341 [18NO]

Federal Food, Drug, and Cosmetic Act: provide greater access to affordable pharmaceuticals (S. 812), S6909, S6930, S6960, S6961, S6963 [17JY], S6978, S7048, S7049, S7050, S7060 [18JY], S7232, S7233 [23JY], S7284, S7316, S7317, S7318 [24JY], S7382 [25JY], S7435 [26JY], S7589, S7590, S7591, S7592, S7593, S7594, S7598, S7601, S7611 [30JY]

Medicare: establish voluntary outpatient prescription drug coverage program and modernize and reform payments and the regulatory structure (H.R. 4954), H3929 [25JN], H4226, H4297 [27JN]

Public Health Service Act: amend relative to pharmacy health professions programs (S. 1806), S9927 [3OC]

Analyses

Preservation of Antibiotics for Human Treatment Act (S. 2508), S4283 [13MY]

Research Revitalization Act (S. 3060), S9994 [4OC]

Articles and editorials

Daschle Blames Bush Tax Cut for Failure on Prescription Drug Reform, S7423 [26JY]

Drug Prices—Why They Keep Soaring, S4273 [13MY]

Finding a Formula for Medicare Drug Benefits, S7623 [31JY]

Jesse Helms—We Cannot Turn Away, S5151 [6JN]

Plug the Flow of ``Incentives'', E1801 [9OC]

Retirement That Hurts RTP, S11722 [20NO]

We Filled the Prescription, E1452 [29JY]

Bills and resolutions

Animals: ensure use of certain antibiotic drugs in agriculture does not compromise human health by contributing to the development of antibiotic resistance (see S. 2508), S4281 [13MY] (see H.R. 3804), H633 [27FE]

Business and industry: eligibility of certain applicants for approval of a generic drug for a competition-free period (see H.R. 4998), H3825 [21JN]

———require prescription drug manufacturers, packers, and distributors to disclose certain gifts provided in connection with promotional or marketing activities (see H.R. 5037), H4324 [27JN]

Canada: grant waivers permitting individuals to import prescription drugs from Canada and amend laws relative to sale of prescription drugs through the Internet (see H.R. 5217), H5789 [25JY]

———permit commercial importation of prescription drugs from Canada (see S. 2244), S3303 [24AP] (see H.R. 4614), H1674 [25AP]

Central Asia: provide assistance to prevent, treat, and control HIV/AIDS, tuberculosis, malaria, polio, and other infectious diseases that affect children (see H.R. 5681), H8022 [16OC]

Dept. of HHS: establish National Vaccine Authority (see H.R. 4100), H1153 [9AP]

Dept. of Veterans Affairs: dispense medications to veterans for prescriptions written by private practitioners (see H.R. 5286), H5995 [26JY]

———establish policies for any requirement that veterans be required to split their medications as a cost-saving measures (see H.R. 4836), H3036 [23MY]

———pilot program to assess benefits of dispensing medications to veterans for prescriptions written by private practitioners (see H.R. 5332), H6059 [4SE]

———suspend authority to increase drug copayment for treatment of non-service-connected disabilities and increase pension rates for certain surviving spouses (see H.R. 5082), H4424 [9JY]

Diseases: address the international HIV/AIDS pandemic (see S. 1936), S660 [12FE]

———combat cancer (see S. 1976), S1351 [28FE] (see H.R. 4596), H1673 [25AP]

———expand assistance to countries seriously affected by HIV/AIDS, malaria, and tuberculosis (see S. 15), S11736 [20NO] (see S. 2525), S4387 [15MY] (see H.R. 5761), H9036 [19NO]

———improve data collection and dissemination between Federal and State registries to enhance the treatment and research of cancer (see S. 2955), S8753 [18SE]

———provide assistance to combat the HIV/AIDS pandemic in developing countries (see S. 2649), S5772 [19JN]

Drugs: correct impediments to allowing importation of prescription drugs into the U.S. by pharmacists and wholesalers for resale and by U.S. citizens for personal use (see H.R. 5534), H6982 [2OC]

———enhance competition for prescription drugs by increasing enforcement of existing antitrust laws relative to brand name and generic drugs (see S. 2677), S6013 [25JN]

———establish an electronic system for practitioner monitoring of the dispensing of certain controlled substances (see S. 3033), S9846 [2OC] (see H.R. 5503), H6783 [30SE]

———establish requirements relative to the sale of, or the offer to sell, prescription drugs through the Internet (see H.R. 4990), H3824 [21JN]

Economic Growth and Tax Relief Reconciliation Act: freeze and repeal portions of the tax reduction and apply savings to a comprehensive Medicare outpatient prescription drug benefit (see H.R. 3757), H366 [13FE]

FDA: establish authority for the imposition of civil penalties for certain direct-to-consumer advertisements (see H.R. 4833), H3036 [23MY]

———require labeling containing information applicable to pediatric patients (see S. 2394), S3505 [29AP] (see H.R. 4730), H2470 [14MY] (see H.R. 5594), H7738 [9OC]

Federal Food, Drug, and Cosmetic Act: ensure competition in pharmaceutical industry and increased access to affordable drugs (see S. 2818), S7469 [29JY]

———establish a program of fees relative to animal drugs (see S. 2665), S5851 [20JN] (see H.R. 4955), H3668 [18JN]

———provide greater access to affordable pharmaceuticals (see H.R. 5272), H5994 (see H.R. 5311), H5996 [26JY] (see H.R. 5350), H6129 [9SE]

———provide greater access to affordable pharmaceuticals (H.R. 1862), consideration (see H. Res. 517), H6085 [5SE]

Foreign trade: importation of certain prescription drugs (see H.R. 5186), H5194 [23JY]

Health: improve immunization rates by increasing the distribution of vaccines and improving and clarifying the vaccine injury compensation program (see S. 2053), S2260 [21MR] (see H.R. 5282), H5995 [26JY]

———improve patient safety and reduce incidence of medical errors (see S. 2590), S5041 [5JN] (see S. 3029), S9846 [2OC] (see H.R. 5478), H6776 [26SE]

———permit an individual to be treated by a health care practitioner with any method of medical treatment such individual requests (see S. 2207), S2950 [18AP]

———provide grants to health care providers to implement electronic prescription drug programs (see H.R. 4989), H3824 [21JN]

———voluntary reporting of medication error information to assist in developing and disseminating recommendations and information on preventing medication errors (see H.R. 4673), H2164 [7MY]

Health care professionals: require that pseudoephedrine be dispensed only upon a written prescription of a licensed practitioner (see H.R. 4690), H2354 [9MY]

Insurance: coverage of prescription drugs (see H.R. 3913), H780 [7MR]

Medicaid: allow States to enter into drug rebate agreements to make prescription drugs available to individuals who are not otherwise eligible for medical assistance (see S. 2536), S4623 [21MY]

———require drug manufacturers to pay rebates to State drug discount programs to participate in Medicaid drug rebate agreements and increase rebate payments to State Medicaid programs (see S. 3142), S10676 [17OC]

Medicare: assure that enrollment in any prescription drug program is voluntary (see H.R. 5236), H5790 [25JY]

———coverage of certain self-administered intramuscular and subcutaneous drugs (see H.R. 5719), H8731 [13NO]

———coverage of chronic disease prescription drugs and disease management services (see H.R. 5219), H5790 [25JY]

———coverage of drugs and biologicals (see H.R. 5167), H4931 [18JY]

———coverage of outpatient prescription drugs (see S. 2625), S5584 [14JN] (see S. 2757), S7033 [18JY] (see H.R. 3626), H78 [24JA] (see H.R. 3684), H141 [5FE] (see H.R. 4751), H2607 [16MY] (see H.R. 4984), H3824 [21JN] (see H. Con. Res. 328), H366 [13FE]

———coverage of outpatient prescription drugs for low-income beneficiaries and provision of stop-loss protection for outpatient prescription drug expenses (see H.R. 4741), H2511 [15MY]

———ensure reimbursement for certain FDA-approved cancer drug therapies administered in hospital outpatient settings (see S. 2795), S7372 [25JY] (see H.R. 5218), H5789 [25JY]

———establish a prescription drug discount card endorsement program (see H.R. 4930), H3561 [13JN]

———establish voluntary outpatient prescription drug coverage program and modernize and reform payments and the regulatory structure (see S. 2, 2729), S6808 [15JY] (see H.R. 4954), H3668 [18JN] (see H.R. 5019), H4068 [26JN]

———establish voluntary outpatient prescription drug coverage program and modernize and reform payments and the regulatory structure (H.R. 4954), consideration (see H. Res. 465), H4068 [26JN]

———establish voluntary outpatient prescription drug coverage program and modernize and reform payments and the regulatory structure (H.R. 4954), consideration (H. Res. 465), same-day consideration (see H. Res. 464), H4067 [26JN]

———establish voluntary outpatient prescription drug discount and security program (see S. 2736), S6867 [16JY]

———express importance of modernization, ensure solvency, and provide coverage options and prescription drug coverage (see S. Res. 269), S4330 [14MY]

———provide beneficiaries with access to prescription drugs at Federal Supply Schedule prices (see H.R. 5154), H4872 [17JY]

———reductions in prescription drug prices for beneficiaries and women with breast cancer (see S. 2747), S6947 [17JY]

———reform (see H.R. 5451), H6558 [24SE]

———require any reductions in payment rates for home respiratory medication nebulizer drugs to be offset by an equal increase in reimbursement for home respiratory medication professional services (see H.R. 4901), H3452 [11JN]

———require Dept. of HHS study on new technology payments under the prospective payment system for hospital outpatient department services (see S. 3041), S9901 [3OC]

———use estate tax revenue to finance an outpatient prescription drug program (see H.R. 4136), H1199 [10AP]

Medicare/Medicaid: conduct studies on comparative effectiveness and cost-effectiveness of prescription drugs that account for high levels of expenditures or use by individuals (see H.R. 4832), H3036 [23MY]

Medicine Equity and Drug Safety Act: implementation (see H. Res. 478), H4497 [10JY]

National Vaccine Injury Compensation Program: amend (see H.R. 3741), H365 [13FE]

NIH: biomedical research funding (see S. Res. 347), S10677 [17OC]

Privacy: prohibit use of patient databases for marketing without the express consent of the patient (see S. 3064), S10040 [7OC]

Public Health Service Act: amend relative to pharmacy health professions programs (see H.R. 4992), H3824 [21JN]

Safety: promote safe and ethical clinical trials of drugs, and other test articles, on people overseas (see H.R. 5249), H5993 [26JY]

———provide protections for human participants in research (see S. 3060), S9983 [4OC]

States: permit requirement of parental consent relative to purchase of prescription drugs or devices for minors (see H.R. 4783), H2734 [21MY]

Tariff: bio-set injection RCC (see H.R. 4226), H1289 [15AP]

———D-mannose (see H.R. 4225), H1289 [15AP]

———ezetimibe (see S. 2093), S2577 [11AP] (see H.R. 4127), H1199 [10AP]

———HIV/AIDS drug (see S. 2172, 2173), S2828 [17AP]

———rhinovirus drug (see S. 2174), S2828 [17AP]

Taxation: apply excise tax to hepatitis A vaccines (see H.R. 4553), H1532 [23AP]

———limit manufacturers' deduction for advertising of FDA approved prescription drugs to the level of research and development expenditures (see S. 2486), S4064 [8MY] (see H.R. 4821), H2944 [22MY]

———treatment of direct-to-consumer advertisements of prescription drugs (see H.R. 5105), H4552 [11JY]

Terrorism: provide incentives to commercial researchers to develop technologies and drugs to prevent and treat illnesses associated with a biological, chemical, or radiological weapons attack (see S. 3148), S10677 [17OC]

Cloture motions

Federal Food, Drug, and Cosmetic Act: provide greater access to affordable pharmaceuticals (S. 812), S7299 [24JY], S7462 [29JY], S7633 [31JY]

———provide greater access to affordable pharmaceuticals (S. 812), motion to proceed, S6798 [15JY], S6883 [17JY]

Cost Estimates

Medicare coverage of outpatient prescription drugs: CBO, S7024 [18JY], S7537 [30JY]

Declarations

$10 Billion for AIDS Treatment—2 Million People Worldwide in Treatment by 2004: International AIDS Conference, H4526 [11JY]

Excerpts

Legislation on the safety of the reimportation of prescription drugs, S6927 [17JY]

Letters

Certify safety and cost savings relative to commercial importation of prescription drugs from Canada: Donna E. Shalala, Dept. of HHS, S6910 [17JY]

———Lester M. Crawford, FDA, S6913 [17JY]

———Tommy G. Thompson, Sec. of HHS, S6910 [17JY]

Greater Access to Affordable Pharmaceuticals Act: Abbey S. Meyers, National Organization for Rare Disorders, Inc., S7641 [31JY]

———Carl B. Feldbaum, Biotechnology Industry Organization, S6994 [18JY], S7570 [30JY]

———Coalition for a Competitive Pharmaceutical Market, S6845 [16JY], S7641, S7648 [31JY]

———D. Michael Fisher, Attorney General of Pennsylvania, S7636 [31JY]

———Dick Wagoner, Jr., General Motors Corp., S7641 [31JY]

———Eliot Spitzer, Attorney General of New York, S7636 [31JY]

———James E. Rogan, Patent and Trademark Office, S7571 [30JY]

———Janell Mayo Duncan, Consumers Union, S7642 [31JY]

———Jody Hunter, Business for Affordable Medicine (organization), S6845 [16JY], S7648 [31JY]

———Kathleen D. Jaeger, Generic Pharmaceutical Association, S7641 [31JY]

———Michael K. Kirk, American Intellectual Property Law Association, S7346 [25JY]

———Senator Kennedy, S7026-S7028 [18JY]

———Stephen Mulloney, Massachusetts Biotechnology Council, S6995 [18JY]

Medicare coverage of outpatient prescription drugs: several health care organizations, S7545 [30JY]

———William D. Novelli, AARP, S10532 [16OC]

———William D. Novelli, Cecil Malone, and Maria Reynolds-Diaz, AARP, S7100 [19JY]

Medicare Modernization and Prescription Drug Act: William D. Novelli, AARP, H4288 [27JN]

Medicare Outpatient Prescription Drug Act: Barbara Kennelly, National Committee To Preserve Social Security and Medicare, S5586 [14JN], S7021 [18JY]

———Charles M. Loveless, American Federation of State, County and Municipal Employees, S5586 [14JN], S7021 [18JY]

———Edward F. Coyle, Alliance for Retired Americans, S5587 [14JN], S7021 [18JY]

———James Firman, National Council on the Aging, S5585 [14JN], S7020 [18JY]

———Kathleen Jaeger, Generic Pharmaceutical Association, S5587 [14JN], S7020 [18JY]

———Ronald F. Pollack, Families USA (organization), S5586 [14JN], S7021 [18JY]

———William D. Novelli, AARP, S5585 [14JN], S7020 [18JY]

———William Samuel, AFL-CIO, S5586 [14JN], S7021 [18JY]

Medicare voluntary outpatient prescription drug discount and security program: William D. Novelli, AARP, S7210, S7217 [23JY], S7283 [24JY]

Mother-to-child HIV/AIDS transmission prevention funding: Senator Helms, Committee on Foreign Relations (Senate), S5152 [6JN]

National Vaccine Injury Compensation Program: Elizabeth J. Noyes, Advisory Commission on Childhood Vaccines, S11178 [15NO]

———Louis Z. Cooper, American Academy of Pediatrics, S11179 [15NO]

Prescription Drug User Fee Act reauthorization: Tommy Thompson, Sec. of HHS, S5195 [6JN]

Preservation of Antibiotics for Human Treatment Act: Mohammad N. Akhter, American Public Health Association, S4283 [13MY]

Lists

FDA approval of buprenorphine for the treatment of heroin addiction press conference participants, S10658 [17OC]

Opponents and supporters of S. 812, Greater Access to Affordable Pharmaceuticals Act, S7638 [31JY]

Supporters of S. 2590, Patient Safety and Quality Improvement Act, S7368 [25JY]

Motions

Drugs: consideration of legislation to provide greater access to affordable pharmaceuticals, H6957 [2OC]

Federal Food, Drug, and Cosmetic Act: provide greater access to affordable pharmaceuticals (S. 812), S7206 [23JY], S7283 [24JY], S7534 [30JY], S7633 [31JY]

Medicare: establish voluntary outpatient prescription drug coverage program and modernize and reform payments and the regulatory structure (H.R. 4954), H4297 [27JN]

Proposals

Consideration of legislation to provide greater access to affordable pharmaceuticals, H6856 [1OC], H6955 [2OC]

Questions and answers

Proposal to provide Medicare coverage of outpatient prescription drugs, S7624 [31JY]

Remarks in House

Advertising: effect of advertising on prescription drug prices, H659 [5MR]

Animals: ensure use of certain antibiotic drugs in agriculture does not compromise human health by contributing to the development of antibiotic resistance (H.R. 3804), H2114 [7MY], E1147 [25JN]

Business and industry: impact of gifts and benefits provided to physicians by prescription drug manufacturers on the efficacy and cost-effectiveness of prescription drugs, E1801 [9OC]

Centers for Disease Control and Prevention: National Pharmaceutical Stockpile Program funding, H6998 [3OC]

Central Asia: provide assistance to prevent, treat, and control HIV/AIDS, tuberculosis, malaria, polio, and other infectious diseases that affect children (H.R. 5681), E1880 [17OC]

Committee on Appropriations (House): appropriations allocation revisions to H.R. 4954, Medicare Modernization and Prescription Drug Act, H4322 [27JN]

Congress: legislative priorities, H6391 [19SE]

Courts: pediatric vaccine manufacturer liability protection, H9089-H9093 [22NO], E2143 [22NO]

Dept. of HHS: authority to administer smallpox vaccine in the event of a smallpox attack or threat, E2041 [14NO]

Dept. of Veterans Affairs: suspend authority to increase copayment for medication furnished on an outpatient basis for treatment of service-connected disabilities (H.R. 2820), H566, H611 [27FE], H770 [7MR]

Diseases: AIDS epidemic, E1248 [12JY]

———combat cancer (H.R. 4596), E1878 [17OC]

———expand assistance to African Americans seriously affected by HIV/AIDS, E110 [7FE], E124 [8FE]

———expand assistance to countries seriously affected by HIV/AIDS, malaria, and tuberculosis, H4531 [11JY]

———improve access to HIV/AIDS-related treatments and services in sub-Saharan Africa and other developing countries, H5225 [23JY]

———research and development of new HIV/AIDS treatments, E1612 [19SE]

Drugs: consideration of legislation to provide greater access to affordable pharmaceuticals, H6955-H6958 [2OC]

———discrepancy in prescription drug prices between U.S. and foreign countries, H659 [5MR], H3207 [5JN], H3427 [11JN], H3495 [12JN], H3581 [17JN], H3645, H3646 [18JN], H3815, H3819 [21JN], H4485-H4491 [10JY], H5068 [22JY]

Federal Employees Health Benefits Program: coverage of contraceptives under any plan providing prescription drug coverage, H4915 [18JY]

Federal Food, Drug, and Cosmetic Act: provide greater access to affordable pharmaceuticals (H.R. 1862), H2110 [7MY], H6268 [17SE], H6377, H6387, H6390, H6393, H6394, H6398 [19SE]

———provide greater access to affordable pharmaceuticals (H.R. 5272), H6261, H6268, H6297 [17SE]

GlaxoSmithKline (company): tribute to efforts under the WHO Lymphatic Filariasis Elimination Program, E1419 [29JY], E1495 [4SE]

Health: voluntary reporting of medication error information to assist in developing and disseminating recommendations and information on preventing medication errors (H.R. 4673), E726 [7MY]

House of Representatives: legislative priorities, H6475-H6478 [24SE]

Immunex Corp.: tribute, H2933 [22MY]

International AIDS Conference: tribute, H4526, H4527, H4533 [11JY], E1257 [15JY]

Medicare: coverage of chronic disease prescription drugs and disease management services (H.R. 5219), E1386 [25JY]

———coverage of drugs and biologicals (H.R. 5167), E1302 [18JY]

———coverage of oral anticancer drugs (H.R. 1624), H2095 [2MY], E1878 [17OC]

———coverage of outpatient prescription drugs, H83, H85 [29JA], H1027, H1052, H1071, H1084 [20MR], H1690 [30AP], H2109, H2133, H2134, H2135, H2136 [7MY], H2169, H2170, H2227-H2233 [8MY], H2648-H2654 [20MY], H2664, H2665, H2815-H2820 [21MY], H2837, H2916, H2919 [22MY], H3076, H3143-H3150 [4JN], H3165, H3166, H3167, H3206 [5JN], H3299, H3300, H3301, H3397, H3398, H3399, H3437-H3442 [11JN], H3495, H3501-H3507 [12JN], H3548 [13JN], H3566, H3587-H3593 [17JN], H4342 [8JY], H4664-H4670 [15JY], H4678 [16JY], H4771 [17JY], H5093, H5094 [23JY], H6032-H6036 [4SE], H6078, H6079 [5SE], H6258, H6259, H6295-H6298 [17SE], H6352-H6357 [18SE], H8062 [12NO], E689 [3MY], E742 [8MY], E773 [10MY], E878 [22MY], E1014 [12JN], E1582 [17SE], E1611 [19SE]

———coverage of outpatient prescription drugs for women, H4075, H4150 [27JN]

———coverage of outpatient prescription drugs (H.R. 3626), H740 [7MR], H910 [14MR]

———coverage of outpatient prescription drugs (H.R. 3684), H4291 [27JN], E71 [5FE]

———establish voluntary outpatient prescription drug coverage program and modernize and reform payments and the regulatory structure (H.R. 4954), H3605, H3610, H3613, H3641, H3652-H3659 [18JN], H3673, H3674, H3676, H3677, H3702, H3712-H3719 [19JN], H3725, H3726, H3727, H3728, H3750, H3753-H3760 [20JN], H3779, H3780, H3781, H3812 [21JN], H3827, H3828, H3841, H3842-H3849, H3852-H3854 [24JN], H3861, H3862, H3864, H3866, H3917-H3920 [25JN], H3932, H3933, H3934, H4030, H4031, H4032, H4039-H4045, H4051-H4056 [26JN], H4073, H4074, H4075, H4076, H4078, H4182-H4320 [27JN], H4330 [8JY], H4356 [9JY], H4578, H4664, H4665 [15JY], H4772 [17JY], H5093, H5094 [23JY], H5321 [24JY], H8027 [17OC], H8760 [14NO], E1107 [20JN], E1199, E1201, E1202, E1203 [8JY], E1220, E1223 [9JY], E1226 [10JY], E1913 [17OC]

———establish voluntary outpatient prescription drug coverage program and modernize and reform payments and the regulatory structure (H.R. 4954), consideration (H. Res. 465), H4166-H4182 [27JN]

———establish voluntary outpatient prescription drug coverage program and modernize and reform payments and the regulatory structure (H.R. 4954), consideration (H. Res. 465), same-day consideration (H. Res. 464), H6241 [12SE]

———establish voluntary outpatient prescription drug coverage program and modernize and reform payments and the regulatory structure (H.R. 4954), motion to recommit, H4318, H4319 [27JN]

———establish voluntary outpatient prescription drug coverage program and modernize and reform payments and the regulatory structure (H.R. 5019), H4029 [26JN], H4338-H4342 [8JY], E1161, E1163 [27JN]

———reductions in prescription drug prices, H6295-H6298 [17SE]

———reductions in prescription drug prices (H.R. 1400), H2650, H2651 [20MY], H3145 [4JN]

———reform, H6696 [26SE]

———reform (H.R. 5451), E1643 [25SE]

National Vaccine Injury Compensation Program: amend (H.R. 3741), H9093 [22NO], E154 [14FE]

Pharmaceuticals: effect of advertising on prescription drug prices, H659 [5MR]

States: provide access and choice for use of generic drugs under Medicaid programs, H539 [26FE]

Ukrop, James: Virginia Pharmacists Association Research and Education Foundation Rx for Excellence Award recipient, E478 [10AP]

Remarks in Senate

Advertising: condemn industry advertising campaign relative to generic drugs, S9182 [25SE]

Animals: ensure use of certain antibiotic drugs in agriculture does not compromise human health by contributing to the development of antibiotic resistance (S. 2508), S4283, S4284 [13MY]

Business and industry: require companies to disclose any gifts or incentives given to doctors or health care providers and require manufacturers to disclose any rebates given to pharmaceutical benefits managers, S7007 [18JY]

Canada: permit commercial importation of prescription drugs from Canada, S4087 [9MY], S6894-S6922, S6925-S6930 [17JY]

———permit commercial importation of prescription drugs from Canada (S. 2244), S3316-S3319 [24AP], S3502 [29AP], S3550-S3552 [30AP], S3793-S3795 [2MY], S5341 [11JN]

Children and youth: amend certain laws relative to pediatric studies of drugs, S5192 [6JN]

Congress: legislative priorities, S8336 [9SE], S8629-S8631 [17SE]

Contraceptives: require equitable coverage of drugs, devices, and services under health insurance plans, S7535 [30JY]

Courts: pediatric vaccine manufacturer liability protection, S11022, S11025 [14NO], S11164, S11168, S11169, S11175-S11181, S11186 [15NO], S11279-S11281, S11286 [18NO], S11360, S11364-S11370 [19NO]

Dept. of HHS: certify safety and cost savings relative to commercial importation of prescription drugs from Canada, S6910-S6922, S6925-S6930 [17JY]

Dept. of Veterans Affairs: tribute to Medical Research Service for research into oral treatment for smallpox, S2406 [9AP]

Diseases: address the international HIV/AIDS pandemic, S7424 [26JY]

———address the international HIV/AIDS pandemic (S. 1936), S664 [12FE]

———AIDS epidemic, S1853 [13MR]

———combat cancer (S. 1976), S1361-S1365 [28FE], S4615 [21MY]

———expand assistance to countries seriously affected by HIV/AIDS, malaria, and tuberculosis, S2241-S2243 [21MR], S5147-S5162, S5195 [6JN], S11543-S11546 [19NO]

———expand assistance to countries seriously affected by HIV/AIDS, malaria, and tuberculosis (S. 2525), S4402-S4404 [15MY], S5779 [19JN]

———improve access to HIV/AIDS-related treatments and services in sub-Saharan Africa and other developing countries, S2241-S2243 [21MR]

———improve access to HIV/AIDS-related treatments and services in sub-Saharan Africa and other developing countries (H.R. 2069), S6679 [11JY], S6700-S6702 [12JY], S11693 [20NO]

———improve access to HIV/AIDS-related treatments and services in the Caribbean nations, S3489 [29AP]

———improve data collection and dissemination between Federal and State registries to enhance the treatment and research of cancer (S. 2955), S8757, S8758 [18SE]

———provide assistance to combat the HIV/AIDS pandemic in developing countries (S. 2649), S5779 [19JN], S5890 [21JN]

Drugs: correct impediments to allowing importation of prescription drugs into the U.S. by pharmacists and wholesalers for resale, S2637-S2639 [15AP]

———enhance competition for prescription drugs by increasing enforcement of existing antitrust laws relative to brand name and generic drugs, S7565-S7571 [30JY], S7645 [31JY]

———enhance competition for prescription drugs by increasing enforcement of existing antitrust laws relative to brand name and generic drugs (S. 2677), S6019 [25JN]

———enhance competition for prescription drugs by increasing enforcement of existing antitrust laws relative to brand name and generic drugs (S. 754), S7460 [29JY], S11339-S11342 [18NO]

———pharmaceutical industry research and development costs, S4273 [13MY]

FDA: approval of buprenorphine for the treatment of heroin addiction, S10655-S10658 [17OC]

———bioequivalence standards for generic drugs, S6993-S6996 [18JY]

———funding, S5171 [6JN], S5284 [10JN]

———require labeling containing information applicable to pediatric patients (S. 2394), S7861 [1AU]

Federal Food, Drug, and Cosmetic Act: establish a program of fees relative to animal drugs (S. 2665), S5862-S5866 [20JN]

———provide greater access to affordable pharmaceuticals (S. 812), S6802, S6811 [15JY], S6873 [16JY], S6883-S6931 [17JY], S6968-S6972, S6976-S7016, S7019-S7028 [18JY], S7093-S7100 [19JY], S7127, S7134-S7158 [22JY], S7180-S7189, S7194, S7218 [23JY], S7244-S7246, S7249-S7263, S7282-S7299 [24JY], S7327-S7336, S7340, S7342-S7350, S7366 [25JY], S7398-S7413, S7423, S7424 [26JY], S7457, S7460, S7464 [29JY], S7505, S7514-S7551, S7565-S7571, S7614-S7616 [30JY], S7618-S7651 [31JY], S7849-S7851, S7853-S7858, S7875-S7878 [1AU], S8630, S8631 [17SE], S9182 [25SE], S10407 [15OC]

———provide greater access to affordable pharmaceuticals (S. 812), motion to proceed, S6797-S6801 [15JY], S6818-S6829, S6831-S6858 [16JY], S6878-S6883 [17JY]

———provide greater access to affordable pharmaceuticals (S. 812), unanimous-consent agreement, S7545 [30JY]

FTC: study on pharmaceutical industry marketing rules, S7460 [29JY]

GlaxoSmithKline (company): tribute to efforts under the WHO Lymphatic Filariasis Elimination Program, S8197 [4SE]

Health: improve immunization rates by increasing the distribution of vaccines and improving and clarifying the vaccine injury compensation program (S. 2053), S2276-S2278 [21MR], S5922 [24JN]

———improve patient safety and reduce incidence of medical errors (S. 2590), S5052, S5053 [5JN], S7367 [25JY]

———improve patient safety and reduce incidence of medical errors (S. 3029), S9848 [2OC]

———permit an individual to be treated by a health care practitioner with any method of medical treatment such individual requests (S. 2207), S2965 [18AP]

International AIDS Conference: tribute, S6815 [16JY]

Medicaid: allow States to enter into drug rebate agreements to make prescription drugs available to individuals who are not otherwise eligible for medical assistance (S. 2536), S4626 [21MY]

Medicare: coverage of outpatient prescription drugs, S2383 [9AP], S2909 [18AP], S3550-S3552 [30AP], S3589-S3591, S3606, S3607 [1MY], S3793-S3795 [2MY], S4087, S4088 [9MY], S4192 [10MY], S4293 [14MY], S4345 [15MY], S4513 [17MY], S4742-S4744, S4824, S4833 [23MY], S4933 [4JN], S5024 [5JN], S5341 [11JN], S5465-S5468 [13JN], S6802, S6811 [15JY], S6814, S6816-S6818 [16JY], S6887, S6890-S6892, S6894, S6922-S6926 [17JY], S6969-S6971, S6976-S6992, S7019-S7026 [18JY], S7095-S7100 [19JY], S7134-S7158 [22JY], S7180-S7189, S7194-S7207, S7216 [23JY], S7244-S7246 [24JY], S7327, S7359, S7366 [25JY], S7423, S7424 [26JY], S7446, S7464 [29JY], S7505, S7514, S7535-S7551, S7565, S7614-S7616 [30JY], S7618-S7633, S7642, S7646, S7647, S7649-S7651 [31JY], S7840, S7849-S7851, S7853-S7858 [1AU], S10408, S10410 [15OC], S10532-S10546 [16OC], S10637, S10655 [17OC]

———coverage of outpatient prescription drugs (S. 10), S4618 [21MY]

———coverage of outpatient prescription drugs (S. 2625), S5585-S5597 [14JN], S5663 [18JN], S5792-S5794 [20JN], S6180-S6182 [27JN], S6600-S6603 [11JY]

———coverage of outpatient prescription drugs (S. 2757), S7041 [18JY]

———ensure reimbursement for certain FDA-approved cancer drug therapies administered in hospital outpatient settings (S. 2795), S7374 [25JY]

———establish voluntary outpatient prescription drug coverage program and modernize and reform payments and the regulatory structure, S6856-S6858 [16JY], S7001-S7005, S7022-S7026 [18JY], S7093-S7100 [19JY], S7134-S7146, S7157 [22JY], S7180-S7189, S7194-S7207, S7210 [23JY], S7464 [29JY], S7514-S7516, S7543-S7547 [30JY], S7621, S7626, S7627 [31JY]

———establish voluntary outpatient prescription drug coverage program and modernize and reform payments and the regulatory structure (H.R. 4954), S5823 [20JN], S6594 [10JY], S6729 [15JY]

———establish voluntary outpatient prescription drug coverage program and modernize and reform payments and the regulatory structure (S. 2), S6811 [15JY], S6873 [16JY]

———establish voluntary outpatient prescription drug coverage program and modernize and reform payments and the regulatory structure (S. 2), unanimous-consent request, S10536 [16OC]

———establish voluntary outpatient prescription drug coverage program and modernize and reform payments and the regulatory structure (S. 2729), S6873-S6875 [16JY]

———establish voluntary outpatient prescription drug discount and security program, S6753 [15JY], S6924-S6926 [17JY], S7207-S7218 [23JY], S7249-S7263, S7282, S7283 [24JY]

———express importance of modernization, ensure solvency, and provide coverage options and prescription drug coverage (S. Res. 269), S4334 [14MY]

———provide adequate coverage of immunosuppressive drugs for certain transplant patients, S7366 [25JY]

———require Dept. of HHS study on new technology payments under the prospective payment system for hospital outpatient department services (S. 3041), S9907 [3OC]

Merck & Co., Inc.: anniversary of MECTIZAN Donation Program, S8558 [12SE]

NIH: biomedical research funding (S. Res. 347), S10730-S10732 [17OC]

Older Americans Act: funding, S4833 [23MY]

Prescription Drug User Fee Act: reauthorization, S5195 [6JN]

Privacy: prohibit use of patient databases for marketing without the express consent of the patient (S. 3064), S10046 [7OC]

Public Health Service Act: amend relative to pharmacy health professions programs (S. 1806), S9927-S9930 [3OC]

Republican Party: national agenda, S3257 [24AP]

Safety: provide protections for human participants in research (S. 3060), S9993 [4OC]

Senate: legislative priorities, S8967 [20SE], S9003 [23SE]

States: clarify authority to enter into drug rebate agreements with manufacturers in order to provide prescription drug coverage to individuals not covered by Medicaid, S6978-S6982, S7010-S7016 [18JY]

Taxation: limit manufacturers' deduction for advertising of FDA approved prescription drugs to the level of research and development expenditures (S. 2486), S4077 [8MY], S4087 [9MY], S4824 [23MY]

Terrorism: provide incentives to commercial researchers to develop technologies and drugs to prevent and treat illnesses associated with a biological, chemical, or radiological weapons attack (S. 3148), S10716-S10728 [17OC]

Reports

Autism—A Novel Form of Mercury Poisoning: Sallie Bernard, Albert Enayati, Lyn Redwood, Heidi Roger, and Teresa Binstock, H9096-H9107 [22NO]

Prescription Drug User Fee Act Reauthorization Performance Goals and Procedures, S5195-S5200 [6JN]

What Do We Know From the Peer-Reviewed Scientific Literature About Thimerosal?, H9093-H9095 [22NO]

Reports filed

Consideration of H.R. 4954, Medicare Modernization and Prescription Drug Act: Committee on Rules (House) (H. Res. 465) (H. Rept. 107-553), H4068 [26JN]

Drug Competition Act: Committee on the Judiciary (Senate) (S. 754) (S. Rept. 107-167), S5850 [20JN]

Greater Access to Affordable Pharmaceuticals Act: Committee on Health, Education, Labor, and Pensions (Senate) (S. 812), S6649 [11JY]

Health Care Providers Grants To Implement Electronic Prescription Drug Programs: Committee on Energy and Commerce (House) (H.R. 4989) (H. Rept. 107-545), H4064, H4067 [26JN]

International AIDS Treatment and Prevention Act: Committee on Health, Education, Labor, and Pensions (Senate) (S. 2649), S6361 [8JY]

Labeling Requirement Containing Information Applicable to Pediatric Patients: Committee on Health, Education, Labor, and Pensions (Senate) (S. 2394) (S. Rept. 107-300), S10114 [8OC]

Medicare Coverage of Outpatient Prescription Drugs: Committee on Energy and Commerce (House) (H.R. 4984) (H. Rept. 107-551), H4064, H4067 [26JN]

Medicare Modernization and Prescription Drug Act: Committee on Ways and Means (House) (H.R. 4954) (H. Rept. 107-539), H4064, H4067 [26JN]

Pharmacy Education Aid Act: Committee on Health, Education, Labor, and Pensions (Senate) (S. 1806), S9595 [30SE]

Public Health Service Act Amendment Relative to Pharmacy Health Professions Programs: Committee on Energy and Commerce (House) (H.R. 4992) (H. Rept. 107-548), H4064, H4067 [26JN]

Require Labeling Containing Information Applicable to Pediatric Patients: Committee on Health, Education, Labor, and Pensions (Senate) (S. 2394), S7898 [1AU]

Requirements Relative to the Sale of, or the Offer To Sell, Prescription Drugs Through the Internet: Committee on Energy and Commerce (House) (H.R. 4990) (H. Rept. 107-546), H4064, H4067 [26JN]

Same-Day Consideration of H. Res. 465, Consideration of H.R. 4954, Medicare Modernization and Prescription Drug Act: Committee on Rules (House) (H. Res. 464) (H. Rept. 107-552), H4067 [26JN]

U.S. Leadership Against HIV/AIDS, Tuberculosis, and Malaria Act: Committee on Foreign Relations (Senate) (S. 2525) (S. Rept. 107-206), S6361 [8JY]

Rulings of the Chair

Drugs: consideration of legislation to provide greater access to affordable pharmaceuticals, H6957 [2OC]

Statements

FDA Approval of Buprenorphine for the Treatment of Heroin Addiction: Charles R. Schuster, Wayne State University, S10657 [17OC]

———Chris-Ellyn Johanson, Wayne State University, S10657 [17OC]

———Herbert Kleber, Columbia University, S10658 [17OC]

———James H. Woods, University of Michigan, S10657 [17OC]

Greater Access to Affordable Pharmaceuticals Act: David Beier, S7346 [25JY]

———Eliot Spitzer, Attorney General of New York, S7637 [31JY]

No Help for Retirees With Employer or Union Coverage From Graham, S7624 [31JY]

Summaries

Biological, Chemical and Radiological Weapons Countermeasures Research Act (S. 3148), S10724 [17OC]

Global Access to HIV/AIDS Prevention, Awareness, Education, and Treatment Act (H.R. 2069), S6701 [12JY]

Tables

AIDS Program funding level, S5156 [6JN]

Cost to States of proposal to provide Medicare coverage of outpatient prescription drugs, S7623 [31JY]

Coverage gap in proposal to provide Medicare coverage of outpatient prescription drugs, S7623 [31JY]

Schedule required to achieve goals of Tripling of Biomedical Research Resolution, S10732 [17OC]

Vaccine mercury burden and autism risk in the U.S., H9108 [22NO]

Testimonies

Autism Epidemic: Lee Grossman, Autism Society of America, H9095 [22NO]

Texts of

H. Res. 465, consideration of H.R. 4954, Medicare Modernization and Prescription Drug Act, H4166 [27JN]

H.R. 4954, Medicare Modernization and Prescription Drug Act, H4182, H4226-H4269 [27JN]

S. 754, Drug Competition Act, S11341 [18NO]

S. 812, Greater Access to Affordable Pharmaceuticals Act, S6884-S6887 [17JY], S8007-S8012 [1AU]

S. 1806, Pharmacy Education Aid Act, S9927-S9930 [3OC]

S. 2053, Improved Vaccine Affordability and Availability Act, S2278-S2281 [21MR]

S. 2244, Prescription Drug Price Parity for Americans Act, S3316-S3318 [24AP]

S. 2486, Fair Advertising and Increased Research (FAIR) Act, S4077 [8MY]

S. 2536, Rx Flexibility for States Act, S4627 [21MY]

S. 2625, Medicare Outpatient Prescription Drug Act, S5587-S5597 [14JN]

S. 2665, Animal Drug User Fee Act, S5863-S5865 [20JN]

S. 2677, Consumer Access to Prescription Drugs Improvement Act, S6020-S6025 [25JN]

S. 3064, Health Records Confidentiality Act, S10047 [7OC]

S. Res. 269, express importance of Medicare modernization, ensure solvency, and provide coverage options and prescription drug coverage, S4334 [14MY]

S. Res. 347, Tripling of Biomedical Research Resolution, S10730 [17OC]